PHAR Pharming Group N.V. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1828316 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $376.13M | $297.20M |
| Cost of revenue | $45.50M | $35.40M |
| Gross profit | $330.63M | $261.80M |
| R&D expense | $100.37M | $83.15M |
| SG&A expense | $79.96M | $70.65M |
| Operating income | $25.84M | -$8.62M |
| Interest expense | $196,000 | $56,000 |
| Pretax income | $12.85M | -$8.49M |
| Income tax | $10.31M | $3.35M |
| Net income | $2.85M | -$11.84M |
| EPS (basic) | 0.00 | -0.02 |
| EPS (diluted) | 0.00 | -0.02 |
| Weighted avg. shares (diluted) | 746.87M | 785.41M |
| Balance sheet | ||
| Cash & equivalents | $145.31M | $54.94M |
| Receivables | $54.70M | $54.82M |
| Inventory | $64.90M | $55.72M |
| Current assets | $299.47M | $278.44M |
| PP&E, netmay include right-of-use assets (IFRS) | $7.23M | $7.75M |
| Intangibles | $135.54M | $61.04M |
| Total assets | $499.96M | $399.99M |
| Current liabilities | $115.79M | $73.80M |
| Total liabilities | $222.86M | $178.92M |
| Shareholders' equity | $277.10M | $221.06M |
| Shares outstanding | 701.68M | 680.31M |
| Cash flow statement | ||
| Operating cash flow | $54.71M | -$1.79M |
| Capital expenditure | $749,000 | $790,000 |
| Free cash flow | $53.96M | -$2.58M |
| Investing cash flow | $26.25M | $31.62M |
| Financing cash flow | $1.50M | -$34.41M |
| Stock-based compensation | $13.77M | $11.25M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.